Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2471-2480 Newer>

The Motley Fool October 31, 2005 Rick Aristotle Munarriz	AOL Founder's New Revolution Steve Case is resigning from Time Warner's board to devote himself to Revolution Health Group. Health care reform has gotten plenty of lip service over the years, but this seems to be a genuine effort to build a better health-care mousetrap online.
The Motley Fool October 31, 2005 Stephen D. Simpson	Kinetic Takes a Flesh Wound Although a recent reimbursement decision was unexpected for this wound care specialist, the stock market seems to have overreacted. Investors, take note.
The Motley Fool October 28, 2005 Stephen D. Simpson	Bristol-Myers' Bad Mojo The possible loss of the experimental diabetes drug Pargluva is a blow to this pharmaceutical that's already hurting for growth. If you're expecting a near-term bang for your investment buck, this might not be the best destination.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
The Motley Fool October 27, 2005 Stephen D. Simpson	What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note.
The Motley Fool October 27, 2005 Stephen D. Simpson	Will Smith & Nephew Keep Flexing? This smaller, British, orthopedic company has competitive products, but industry trends could hurt it. However, the entire orthopedic sector is getting pretty interesting from a value perspective.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool October 27, 2005 Stephen D. Simpson	AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here.
Bio-IT World October 2005 Lorna Jack	Biotech Beckons in Bonny Scotland U.S. biotechs are commonly attracted to Scotland because of the excellent opportunities available for collaboration with biomedical innovators.
Bio-IT World October 2005 John Russell	Compugen Transforms Its Business Many informatics pioneers discovered the hard way that selling software licenses and fee-for-services can't always pay the bills. Tel Aviv-based Compugen, is working to reinvent itself as a drug discovery and development player.
<Older 2471-2480 Newer> Return to current articles.